Oppenheimer Increases Constellation Pharmaceuticals (NASDAQ:CNST) Price Target to $40.00

Constellation Pharmaceuticals (NASDAQ:CNST) had its price objective raised by Oppenheimer from $18.00 to $40.00 in a research note issued to investors on Wednesday, The Fly reports.

Other research analysts have also recently issued research reports about the stock. ValuEngine cut shares of Constellation Pharmaceuticals from a hold rating to a sell rating in a report on Tuesday, October 15th. Royal Bank of Canada started coverage on shares of Constellation Pharmaceuticals in a report on Wednesday, September 4th. They issued an outperform rating and a $20.00 target price for the company. Finally, Zacks Investment Research raised shares of Constellation Pharmaceuticals from a sell rating to a buy rating and set a $8.75 target price for the company in a report on Wednesday, October 9th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company’s stock. Constellation Pharmaceuticals has an average rating of Buy and an average target price of $36.96.

CNST traded down $0.91 during trading on Wednesday, reaching $30.91. 940,000 shares of the stock were exchanged, compared to its average volume of 139,883. The stock has a market cap of $381.40 million, a P/E ratio of -6.18 and a beta of 5.32. The company has a debt-to-equity ratio of 0.44, a quick ratio of 5.85 and a current ratio of 5.85. Constellation Pharmaceuticals has a twelve month low of $4.01 and a twelve month high of $45.42. The stock’s 50 day moving average price is $11.58 and its two-hundred day moving average price is $10.07.

Constellation Pharmaceuticals (NASDAQ:CNST) last posted its earnings results on Wednesday, November 6th. The company reported ($0.82) EPS for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.01. Equities research analysts predict that Constellation Pharmaceuticals will post -2.99 earnings per share for the current fiscal year.

In other news, major shareholder Group L. P. Column acquired 1,411,764 shares of the stock in a transaction dated Thursday, October 3rd. The stock was bought at an average price of $8.50 per share, with a total value of $11,999,994.00. Also, insider Adrian Senderowicz sold 27,232 shares of the company’s stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $30.91, for a total value of $841,741.12. Insiders sold 130,855 shares of company stock valued at $3,775,855 in the last ninety days. 43.70% of the stock is currently owned by insiders.

Several institutional investors have recently added to or reduced their stakes in CNST. Acadian Asset Management LLC acquired a new position in shares of Constellation Pharmaceuticals in the second quarter valued at approximately $61,000. Wells Fargo & Company MN increased its stake in shares of Constellation Pharmaceuticals by 42.1% in the second quarter. Wells Fargo & Company MN now owns 13,937 shares of the company’s stock valued at $171,000 after buying an additional 4,132 shares during the period. Jacobs Levy Equity Management Inc. acquired a new position in shares of Constellation Pharmaceuticals in the second quarter valued at approximately $329,000. Alps Advisors Inc. acquired a new position in shares of Constellation Pharmaceuticals in the second quarter valued at approximately $663,000. Finally, P.A.W. Capital Corp increased its stake in shares of Constellation Pharmaceuticals by 33.3% in the third quarter. P.A.W. Capital Corp now owns 160,000 shares of the company’s stock valued at $1,034,000 after buying an additional 40,000 shares during the period. 65.71% of the stock is owned by institutional investors.

Constellation Pharmaceuticals Company Profile

Constellation Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include CPI-0610 that is in Phase II clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib; and CPI-1205 that is in Phase Ib/II clinical trials for the treatment of metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors.

Recommended Story: Trade War

The Fly

Analyst Recommendations for Constellation Pharmaceuticals (NASDAQ:CNST)

Receive News & Ratings for Constellation Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Constellation Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit